Abstract：Objective To observe the therapeutic effect of intranasal corticosteroid mometasone furoate against ocular symptoms of patients with seasonal allergic rhinitis.Methods A total of 156 patients were recruited according to the primary nasal and ocular symptoms of seasonal allergic rhinitis between August 2016 and April 2017. We made a four-grade (none=0, mild=1, moderate= 2, severe=3) self-assessment scale. The first score was assessed by physicians as baseline before administration. Then, the patients received momestasone furoate spray 200 μg once daily (50 μg twice for one nostril), and the nasal and ocular symptom scores were assessed by patients before daily administration. The total nasal and ocular scores were calculated and compared with baseline to assess the therapeutic effect.Results 103 patients completed the study. The total nasal and ocular symptom scores were reduced remarkably 24h after the first medication. The total nasal symptom score became stable after medication twice, and the total ocular symptom score became stable after four-time medication. The significant difference of the total nasal and ocular symptom scores between these groups was confirmed with ANOVA (nasal symptom: F=533.500,P＜0.01; ocular symptom: F=362.188,P＜0.01). No adverse events were found during the treatment.Conclusions Intranasal corticosteroin mometasone furoate can relieve both nasal and ocular symptoms significantly. This single agent can be used to relieve the symptoms of seasonal allergic rhinitis with ocular problems effectively.
Ciprandi G, Cirillo I, Vizzaccaro A, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? [J]. Allergy, 2005, 60(7): 882-887.
[3]
Pitt A D, Smith A F, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire [J]. Ophthalmic Epidemiol, 2004, 11(1): 17-33.
[4]
Smith A F, Pitt A D, Rodruiguez A E, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting [J]. Ophthalmic Epidemiol, 2005, 12(4): 233-242.
[5]
Virchow J C, Kay S, Demoly P, et al. Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients - an observational, cross sectional study in four countries in Europe [J]. J Med Econ, 2011, 14(3): 305-314.
[6]
Bousquet J, Hellings P W, Agache I, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine inrhinitis and asthma across the life cycle [J]. Clin Transl Allergy, 2016, 6:47.
[7]
Weiner J M, Abramson M J, Puy R M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials [J]. BMJ, 1998, 317(7173):1624-1629.
[8]
Bielory L. Ocular allergy overview [J]. Immunol Allergy Clin North Am, 2008, 28(1):1-23.
[9]
Blaiss M S. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids[J]. Curr Med Res Opin, 2008, 24(3):821-836.
[10]
Baroody F M, Foster K A, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis [J]. Ann Allergy Asthma Immunol, 2008, 100(3):194-199.
[11]
Baena-Cagnani C E, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis[J]. Curr Med Res Opin, 2010, 26(9):2047-2055.
[12]
Ozturk F, Yuceturk A V, Kurt E, et al. Evaluation of intraocular pressure and cataract formation following the longterm use of nasal corticosteroids[J]. Ear Nose Throat J, 1998, 77(10):846-851.
[13]
Derby L, Maier W C. Risk of cataract among users of intranasal corticosteroids [J]. J Allergy Clin Immunol, 2000, 105(5): 912-916.
2018, Vol. 29 
